Arcturus Therapeutics
ARCT
42 hedge funds and large institutions have $34.2M invested in Arcturus Therapeutics in 2016 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 14 increasing their positions, 12 reducing their positions, and 7 closing their positions.
105% more call options, than puts
Call options by funds: $1.14M | Put options by funds: $555K
17% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 12
8.44% more ownership
Funds ownership: 0% → 8.44% (+8.4%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less funds holding
Funds holding: 43 → 42 (-1)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
21% less capital invested
Capital invested by funds: $43M → $34.2M (-$8.85M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$1.09M |
| 2 |
RA
Royce & Associates
New York
|
+$1.08M |
| 3 |
JGC
J. Goldman & Co
New York
|
+$555K |
| 4 |
KCM
Kingdon Capital Management
New York
|
+$541K |
| 5 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$305K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$5.05M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$954K |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$522K |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$320K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$149K |
ARCT Hedge Fund Activity: Q4 2016 in Review
42 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q4 2016, worth a combined $34.2M — down 21% from $43M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of ARCT and 6 opened new positions — a net loss of 1 holder — while 12 trimmed existing stakes and 14 added.
The largest buyer was Franklin Resources, adding an estimated $1.09M. The largest seller was RA Capital Management, exiting entirely with an estimated $5.05M sold.
- 42 institutional investors held Arcturus Therapeutics (ARCT) as of Q4 2016, down from 43 in Q3 2016.
- Funds reported $34.2M of Arcturus Therapeutics stock for Q4 2016, down 21% quarter-over-quarter.
- 6 funds opened new Arcturus Therapeutics positions in Q4 2016 and 7 closed out, a net change of -1 holder.
- The largest Arcturus Therapeutics buyer in Q4 2016 was Franklin Resources, an estimated $1.09M added.
- The largest Arcturus Therapeutics seller in Q4 2016 was RA Capital Management, an estimated $5.05M sold.
Based on aggregated 13F filings for Q4 2016.